ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Arsanis, Inc. (“Arsanis” or the “Company”) (NASDAQ: ASNS) complied with the federal securities laws. On June 28, 2018, Arsanis announced the discontinuation of its Phase 2 clinical trial of ASN100, a preventive drug for mechanically ventilated patients with a high risk of contracting pneumonia. Arsanis disclosed that an analysis completed by an independent drug review committee found that continuing the trial was “futile” because the target primary end-point likely would not be met upon completion. The price of Arsanis stock fell significantly following the report.
If you purchased Arsanis common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Alexandria P. Rankin, Esq. at firstname.lastname@example.org, or call the firm by toll-free telephone at (888) 508-6832.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.